Skan Group Ag · SIX:SKAN
Skan — Investor Presentation (September 2026)
21 slides from Skan's investor presentation, September 2026
Slide 1: SKAN Group Investor Presentation
SKAN Group Investor Presentation September 2026
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This pr
Slide 3: Why does aseptic manufacturing matter?
The challenge Why does aseptic Safe medicines depend on safe and controlled processes. manufacturing matter? 01 Drug product • Protecting products and operators • Protecting patients • Process integrity 02 Critical aseptic manufacturing process • Regulatory confidence Every 3rd vaccine 03 Safe medic
Slide 4: Isolators are mission critical for aseptic production processes
The solution: Medication sterility Isolators are mission critical for aseptic production processes CLEANROOM + Filling / closing in cleanroom with terminal sterilization TRADITIONAL SAL 10-3 PHARMA - Inappropriate for complex biopharmaceuticals Probability of 1 in 1,000 of Pharma products finding a
Slide 5: From Swiss roots to global aseptic expertise
Our history From Swiss roots to global aseptic expertise 1968 Today The beginning Aseptic Process Integrity Founded in Allschwil as a trading company for Scandinavian For biopharmaceutical manufacturing healthcare equipment. Hasler Maschinen- IPO at SIX und Apparate acquired Production plant, Swiss
Slide 6: Strong value proposition and high entry barriers
Technological edge and innovation Strong value proposition and high entry barriers HVAC engineering Fabrication know-how Electron beam transfer Filling technology & air flow modelling Selected customers GMP documentation & qualification Chemical know-how on cleaning of equipment validation Automatio
Slide 7: Why SKAN
Expertise Why Scientific reliability Swiss engineering excellence SKAN SKAN does not only respond to evolving standards – our experts actively contribute to shaping industry guidance and best practices. Regulatory Close customer leadership partnership September 2026 SKAN Group AG Investor Presentati
Slide 8: One integrated SKAN ecosystem
Our ecosystem One integrated SKAN ecosystem By combining these capabilities, SKAN orchestrates the entire aseptic manufacturing process: one integrated approach to safe and reliable aseptic manufacturing. Aseptic Process Integrity Services and Consumables Equipment and Solutions Sterile Formats & Si
Slide 9: Global expertise. Close to our customers.
Global presence Global expertise. Close to our customers. Europe North America South America Asia Allschwil & Stein CH Headquarters, production, R&D, labs Görlitz DE Production, steelwork, assembly Raleigh, North Carolina São Paulo Okinawa Ljubljana SI Metronik: software solutions, MES Sales & servi
Slide 10: Structural growth drivers support SKAN’s expansion
Market trends Structural growth drivers support SKAN’s expansion Growth drivers for the biopharmaceutical market Growth drivers for isolators in fill finish Demographic trend Development process Double digit growth of Complex molecules Containment during Isolator technology and lifestyle promote of
Slide 11: SKAN Group’s growth strategy
Way forward SKAN Group’s growth strategy Objectives Continue growth track-record Increase recurring revenue base Strengthen profitability 1 2 3 4 Expand addressable Accelerate growth in Accelerate digital Fortify market leadership market services & consumables transformation ▪ Continuous innovation
Slide 12: Accelerated go-to-market for our customers – enabling faster access for patients
Pre-Approved Services Accelerated go-to-market for our customers – enabling faster access for patients Pre-Approved services … speed up time to market and increase value Design & Manufacturing & Commissioning & Stability studies and Authority approval engineering assembling qualification tech transf
Slide 13: SKAN offers holistic solutions across the pharmaceutical value chain
Integrated offering SKAN offers holistic solutions across the pharmaceutical value chain MePIS MES SKAN offers holistic solutions across the Manufacturing Execution pharmaceutical value chain by combining System isolators, single-use systems and software. The combination of SKAN's aseptic expertise
Slide 14: Expanded offering of single-use systems
Accelerate growth in services & consumables Expanded offering of single-use systems SKAN is a leading innovator in patented 01 Alpha stainless steel door secure rapid transfer systems, enhancing Assembly on isolators efficiency in pharmaceutical production. Receive beta containers or betabags Severa
Slide 15: Highlights of the Half-Year 2026
Financial results Highlights of the Half-Year 2026 Order Intake Net Sales First-half results showed a strong improvement across all key in CHF million in CHF million financial metrics compared to the prior year. Order intake increased 16.3%, reflecting renewed market 247.6 164.5 momentum in the U.S.
Slide 16: Achievements in HY 2026
Strategy execution Achievements in HY 2026 Objectives Continue growth track-record Increase recurring revenue base Strengthen profitability 1 2 3 4 Expand addressable Accelerate growth in Accelerate digital Fortify market leadership market services & consumables transformation ▪ Won most of the larg
Slide 17: Strong market drivers, confident business outlook
Outlook Strong market drivers, confident business outlook Market development Business development Structural growth drivers remain attractive Well positioned to benefit from market trends and continue delivering double-digit growth – Rising demand for quality, automation, containment and regulatory
Slide 18: Guidance and mid-term outlook
Financial targets Guidance and mid-term outlook Metric 2026 Targets Mid-Term targets (1) Group net sales growth Upper teens Mid- to upper teens (2) Segment net sales growth E&S S&C E&S S&C EBITDA margin 13 - 15% Gradually increase profitability level to upper teens in the mid-term. Potential for fur
Slide 19: Shift toward injectable biotech drugs continues and drives need for aseptic process solutions
Structural growth Shift toward injectable biotech drugs continues and drives need for aseptic process solutions 0% of top 10 drugs in 50% of top 10 drugs in 80% of top 10 drugs 2005 injectable dosage form 2020 injectable dosage form 2025 injectable dosage form Eylea Lipitor Zoloft Humira Keytruda Mo
Slide 20: SKAN’s investment highlights
SKAN’s investment highlights 1 Market leader globally for 2 Technology & innovation 3 Strategically positioned in a 4 Significant barriers to high-end aseptic process leadership dynamic & growing niche entry solutions market 5 Trusted, long-term partner 6 Experienced & 7 Excellent financial profile
Slide 21: To protect and secure life.
To protect and secure life.